{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055630","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.885382+00:00","generated_at":"2026-06-02T11:57:25.606078+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Olema reports Q1 net loss of $31.0M; cash $249M; enrollment complete in two palazestrant combo studies","bullets":["Net loss of $31.0M for Q1 2024 vs $28.3M a year ago; cash & equivalents $249.0M.","GAAP R&D expenses $29.9M, including $5.0M milestone to Aurigene for KAT6 program.","Completed enrollment in 60-patient Phase 1b/2 studies of palazestrant + ribociclib and + palbociclib.","New clinical data for palazestrant+ribociclib at ESMO Breast Cancer May 15-17; investor call May 15.","Expect IND for OP-3136 (KAT6 inhibitor) in late 2024; plan Phase 1b/2 palazestrant+everolimus in Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055630","json":"https://secwatch.observer/filing/0000950170-24-055630.json","markdown":"https://secwatch.observer/filing/0000950170-24-055630.md","text":"https://secwatch.observer/filing/0000950170-24-055630.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024055630/0000950170-24-055630-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024055630/olma-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T11:57:25.606078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5dcac5b873a60207979bb31108c8acf06cbf654c","claim":"Olema Pharmaceuticals, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $31.0 million.","evidence_excerpt":"On May 8, 2024, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024055630/0000950170-24-055630-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the quarter ended March 31, 2024, was $31.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}